Trial Profile

A Phase 1, Open-label, Multicenter Study of ZW171 in Participants With Advanced or Metastatic Ovarian Cancer, Non-small Cell Lung Cancer (NSCLC), and Other Mesothelin Expressing Cancers

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 28 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ZW 171 (Primary)
Indications Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Zymeworks

22 May 2025 According to a Zymeworks media release, data from this study will be presented at American Society of Clinical Oncology (ASCO) Annual Meeting from May 31-June 4, 2025 in Chicago, IL.
25 Apr 2025 Results were presented in a Zymeworks media release.
25 Apr 2025 According to a Zymeworks media release, company announced that data from this trial were presented at the American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025 in Chicago, IL.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com